Wellnex Life Limited (ASX:WNX) Announces A$9 Million Commitments for AIM Dual Listing
Wellnex Life Limited (ASX:WNX) secures A$9 million in commitments for its AIM dual listing, enabling significant cost savings and supporting future growth.

Wellnex Life Limited (ASX:WNX) secures A$9 million in commitments for its AIM dual listing, enabling significant cost savings and supporting future growth.
Artrya Limited (ASX:AYA) secures A$15 million through a two-tranche placement to advance its Salix® AI platform’s regulatory and commercial initiatives.
Imugene Limited (ASX:IMU) reports a 57% complete response rate in its Phase 1b CAR-T trial for relapsed/refractory DLBCL.
HealthCo Healthcare & Wellness REIT (ASX:HCW) reports a 5% growth in FFO/unit and DPU for 1H FY25, reaffirming its FY25 guidance.
AVITA Medical (ASX:AVH) reports a 30% revenue increase in Q4 and FDA approvals, setting the stage for significant growth in FY 2025.
Cochlear Limited (ASX:COH) reports a 5% revenue increase and an 8% interim dividend rise for the half year ended December 2024.
RECCE PHARMACEUTICALS Ltd (ASX:RCE) has temporarily paused trading in its securities pending a further announcement.
Althea Group Holdings (ASX:AGH) revises its FY25 revenue guidance to $26-$33 million and adjusts EBITDA expectations amidst strategic restructuring.
Neurotech International Ltd (ASX:NTI) signs a development agreement with RH Pharma to develop cannabinoid therapies for pediatric neurological disorders.
Micro-X Limited (ASX:MX1) raises $6.0M through entitlement and placement offers to advance its medical imaging technology.